202 related articles for article (PubMed ID: 27757561)
1. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
5. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
[TBL] [Abstract][Full Text] [Related]
8. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
9. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
Sato E; Torigoe T; Hirohashi Y; Kitamura H; Tanaka T; Honma I; Asanuma H; Harada K; Takasu H; Masumori N; Ito N; Hasegawa T; Tsukamoto T; Sato N
Clin Cancer Res; 2008 Nov; 14(21):6916-23. PubMed ID: 18980986
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy.
Togashi A; Katagiri T; Ashida S; Fujioka T; Maruyama O; Wakumoto Y; Sakamoto Y; Fujime M; Kawachi Y; Shuin T; Nakamura Y
Cancer Res; 2005 Jun; 65(11):4817-26. PubMed ID: 15930302
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
[TBL] [Abstract][Full Text] [Related]
13. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
[TBL] [Abstract][Full Text] [Related]
16. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
17. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ
Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994
[TBL] [Abstract][Full Text] [Related]
18. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
19. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients.
Suekane S; Nishitani M; Noguchi M; Komohara Y; Kokubu T; Naitoh M; Honma S; Yamada A; Itoh K; Matsuoka K; Kanayama H
Cancer Sci; 2007 Dec; 98(12):1965-8. PubMed ID: 17919310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
